PALX · Palomino Laboratories Inc.

Pursuant to the terms of a certain Share Exchange Agreement and Plan of Reorganization, dated as of July 31, 2026, by and among Palomino Laboratories Inc. (the "Purchaser"), Vega Links, Inc. ("VLI") and the stockholders as listed on Schedule A attached thereto (the "Stockholders"), the Stockholders, who directly owned one hundred percent (100%) of the shares of VLI (the "Shares"), sold all the Shares to the Purchaser in exchange for 4,472,000 shares of the common stock, par value $0.0001 per share of the Purchaser ("Purchaser Stock"). As part of this transaction, Richard Ogawa, as a shareholder of VLI, received 120,000 shares of Purchaser Stock in exchange for his 300,000 shares of VLI.

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

Pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of September 29, 2025, and pursuant to the terms of a stock cancellation agreement, the reporting person voluntarily surrendered and cancelled for no consideration 1,000,000 shares of Issuer's common stock in connection with the consummation of the Merger on September 29, 2025. Matthew Eitner has the power to vote and to dispose of the shares held by Lucius Partners LLC and may be deemed the beneficial owner of the shares.

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).